Document Detail

Enzymatic synthesis of glycosaminoglycan heparin.
MedLine Citation:
PMID:  17629842     Owner:  NLM     Status:  MEDLINE    
Heparin and its low molecular weight heparin derivatives, widely used as clinical anticoagulants, are acidic polysaccharide members of a family of biomacromolecules called glycosaminoglycans (GAGs). Heparin and the related heparan sulfate are biosynthesized in the Golgi apparatus of eukaryotic cells. Heparin is a polycomponent drug that currently is prepared for clinical use by extraction from animal tissues. A heparin pentasaccharide, fondaparinux, has also been prepared through chemical synthesis for use as a homogenous anticoagulant drug. Recent enabling technologies suggest that it may now be possible to synthesize heparin and its derivatives enzymatically. Moreover, new technologies including advances in synthetic carbohydrate synthesis, enzyme-based GAG synthesis, micro- and nano-display of GAGs, rapid on-line structural analysis, and microarray/microfluidic technologies might be applied to the enzymatic synthesis of heparins with defined structures and exhibiting selected activities. The advent of these new technologies also makes it possible to consider the construction of an artificial Golgi to increase our understanding of the cellular control of GAG biosyntheses in this organelle.
Robert J Linhardt; Jonathan S Dordick; Paul L Deangelis; Jian Liu
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  33     ISSN:  0094-6176     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-16     Completed Date:  2007-09-27     Revised Date:  2014-09-22    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  453-65     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / metabolism*
Cell-Free System / enzymology
Glycosaminoglycans / biosynthesis*
Golgi Apparatus / enzymology*
Heparin / biosynthesis*
Polysaccharides / biosynthesis*
Grant Support
R01 HL062244/HL/NHLBI NIH HHS; R01 HL062244-05A1/HL/NHLBI NIH HHS; R01 HL062244-07/HL/NHLBI NIH HHS; R41 RR023764/RR/NCRR NIH HHS; R41 RR023764-01/RR/NCRR NIH HHS
Reg. No./Substance:
0/Anticoagulants; 0/Glycosaminoglycans; 0/Polysaccharides; 0/glucosaminoglycans; 9005-49-6/Heparin; J177FOW5JL/fondaparinux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The vein of Marshall as a source of various types of atrial arrhythmias, including adrenergic paroxy...
Next Document:  Structural modification induced in heparin by a Fenton-type depolymerization process.